rheumatoid
arthriti
ra
common
complex
multifactori
joint
relat
autoimmun
inflammatori
diseas
unknown
etiolog
accomplish
increas
cardiovascular
risk
ra
character
clinic
find
synovi
inflamm
autoantibodi
product
cartilagebon
destruct
cardiovascular
pulmonari
skelet
disord
proinflammatori
cytokin
respons
induct
inflamm
ra
patient
drawback
poor
efficaci
higher
dose
frequent
administr
low
respons
higher
cost
seriou
side
effect
associ
convent
dosag
form
ra
treatment
nanomedicin
recent
gain
interest
toward
treatment
ra
research
also
focus
toward
develop
variou
antiinflammatori
drug
load
nanoformul
aid
activelypass
target
inflam
site
afford
effect
treatment
regimen
ra
alter
surfac
area
nanoscal
size
nanoformul
elicit
benefici
physic
chemic
properti
better
pharmacolog
activ
drug
load
nanoformul
may
enhanc
solubl
poorli
water
solubl
drug
improv
bioavail
afford
target
may
improv
therapeut
activ
regimen
present
review
focu
toward
novel
nanoparticul
formul
nanoparticl
nanoemuls
solid
lipid
nanoparticl
nanomicel
nanocapsul
util
treatment
ra
recent
advanc
sirna
peptid
target
base
nanoparticul
system
ra
treatment
also
discuss
special
emphasi
provid
regard
pathophysiolog
preval
symptom
toward
develop
ra
indian
popul
variou
factor
diseas
activ
socioeconom
educ
statu
bodi
mass
index
spiritu
age
gender
affect
ra
patient
qualiti
life
ra
vari
significantli
osteoarthr
degen
joint
diseas
affect
joint
function
fig
gastrointestin
disturb
renal
malfunct
increas
cardio
vascular
risk
also
associ
ra
system
manifest
subcutan
nodul
pleuriti
pericard
vascul
contribut
morbid
mortal
ra
develop
ra
develop
seem
stronger
men
associ
cigarett
smoke
women
occurr
ra
unidentifi
presum
environment
factor
may
contribut
develop
genet
suscept
individu
genet
compon
environment
factor
influenc
subsequ
immun
respons
studi
report
multipl
cell
type
includ
b
cell
cell
macrophagessynoviocyt
serv
key
regul
immunolog
event
ra
year
interact
environment
factor
along
genet
patient
associ
ra
develop
import
environment
risk
factor
ra
develop
coffeealcohol
intak
oral
contracept
usag
birth
weight
irregular
breast
feed
variou
symptom
associ
ra
develop
shown
fig
pathogenesi
ra
evok
cytokin
control
wide
varieti
inflammatori
process
rheumatoid
joint
imbal
pro
antiinflammatori
cytokin
activ
induc
autoimmun
chronic
inflamm
therebi
caus
joint
damag
fig
cell
prolifer
cascad
immun
system
releas
activ
b
cell
macrophag
therebi
induc
cytokin
tnf
interleukin
il
ra
diagnosi
confirm
patholog
inflammatori
respons
may
lead
joint
destruct
extraarticular
complic
extraarticular
complic
may
occur
time
induc
infect
lymphoma
cardiovascular
diseas
osteoporosi
cytokin
play
major
role
due
destruct
effect
bone
articular
cartilag
provid
rational
current
ra
treatment
strategi
toward
usag
monoclon
antibodi
tumor
necrosi
factor
tnf
proinflammatori
cytokin
play
major
role
regul
inflammatori
respons
especi
ra
condit
treatment
option
complet
recoveri
ra
treatment
may
address
decreas
joint
pain
inflamm
protect
articular
structur
manag
arthrit
condit
involv
interdisciplinari
approach
includ
physic
therapi
modal
associ
medic
manag
past
year
major
advanc
treatment
ra
includ
aggress
use
diseasemodifi
antirheumat
drug
develop
immun
therapi
target
toward
cell
specif
ra
immunopathogenesi
pathogenesi
ra
develop
display
fig
major
manifest
ra
categor
three
includ
bone
airway
cardiovascular
system
case
bone
manifest
bone
affect
local
system
local
factor
stimul
osteoclast
result
increas
bone
resorpt
osteoclast
releas
inflammatori
fibroblast
pannu
cell
mostli
ra
patient
prone
bisphosphon
therapi
osteoporosi
prevent
glucocorticoidmedi
bone
loss
airway
manifest
ra
includ
cricoarytenoid
arthriti
pulmonari
fibrosi
small
airway
diseas
typic
seen
bronchiol
obstruct
abnorm
lung
function
lung
diseas
predomin
ra
patient
especi
male
seroposit
smoker
ra
patient
hold
increas
risk
mortal
lead
increas
incid
cardiovascular
diseas
elev
level
inflammatori
marker
ra
effect
manag
antirheumat
drug
methotrex
mtx
leflunomid
sulfasalazin
hydroxychloroquin
combin
withwithout
differ
nonsteroid
antiinflammatori
drug
aspirin
celecoxib
diclofenac
ibuprofen
indomethacin
ketoprofen
etc
among
drug
mtx
consid
effect
drug
sinc
inspit
also
develop
formul
use
mtx
anoth
drug
combin
effect
treatment
ra
addit
glucocorticoid
gc
also
wide
use
effect
manag
ra
gc
use
monotherapi
materi
today
commun
well
combin
agent
long
term
administr
gc
may
lead
antiinflammatori
remuner
action
structur
damag
wide
util
gc
methylprednisolon
triamcinolon
prednison
hydrocortison
glucocorticoid
inject
inhibitor
tcell
activ
inhibitor
bcell
deplet
inhibitor
jak
inhibitor
immunosuppress
steroid
also
highli
effect
treatment
ra
use
combin
therapi
ra
treatment
follow
past
year
year
least
one
third
patient
ra
treat
combin
therapi
india
tradit
approach
manag
ra
also
chang
monotherapi
combin
approach
differ
treatment
method
adopt
ra
shown
fig
variou
convent
dosag
form
avail
treatment
ra
includ
tablet
capsul
oral
liquid
topic
product
parenter
paediatricgeriatr
product
transderm
patch
topic
dosag
form
treatment
ra
includ
ointment
cream
gel
past
transderm
patch
topic
drug
deliveri
system
deliv
medic
skin
noninvas
manner
major
drawback
associ
convent
dosag
form
treatment
ra
poor
patienc
complianc
short
halflif
low
bioavail
poor
solubl
may
improv
modifi
novel
dosag
form
novel
dosag
form
avail
ra
treatment
includ
microparticl
nanoparticl
nanoemuls
nanomicel
nanodispers
nanocapsul
nanosuspens
etc
convent
dosag
form
avail
treatment
ra
display
tabl
tablet
aspirin
bayer
empirin
inhibit
activ
cyclooxygenas
therebi
decreas
prostaglandin
product
celecoxib
celebrex
special
inhibit
analges
properti
low
toxic
sulfasalazin
azulfidin
inhibit
dihydrofol
reductas
leflunomid
arava
immun
modulatori
effect
inhibit
mitochondri
enzym
dihydroorot
dehydrogenas
indomethacin
indocin
indocinsr
analges
antipyret
antiinflammatori
decreas
prostaglandin
synthesi
minocin
dynacin
bind
bacteri
ribosom
subunit
inhibit
synthesi
protein
oxaprozin
daypro
induc
cyclooxygenas
inhibit
analges
antiinflammatori
activ
cyclosporin
gengraf
neoral
exhibit
potent
immunosuppress
properti
block
transcript
cytokin
activ
cell
sulfasalazin
azulfidin
exhibit
antibacteri
antiinflammatori
effect
act
immuno
modul
scaveng
reactiv
oxygen
metabolit
block
product
prostaglandin
leukotrien
tofacitinib
xeljanz
xeljanz
xr
inhibit
janu
kinas
enzym
interfer
jakstat
signal
pathway
therebi
influenc
dna
transcript
process
azathioprin
azasan
imuran
act
immunosuppress
agent
block
de
novo
pathway
purin
synthesi
therebi
stop
dna
replic
process
doxorubicin
adriamycin
doxil
caelyx
intercal
dna
distort
polynucleotid
structur
result
enzym
inhibit
relat
dna
replic
transcript
topic
oinment
gel
hydroxi
chloroquin
plaquenil
act
antimalari
agent
also
exert
benefici
effect
lupu
elicit
acut
chronic
rheumatoid
arthriti
piroxicam
felden
inhibit
prostaglandin
synthesi
decreas
creation
igm
rheumatoid
factor
inhibitor
cyclooxygenas
arachidon
acid
metabol
oterxup
rheumatrex
exhibit
antagonist
effect
folic
acid
metabol
function
antimetabolit
inhibit
dihydrofol
reductas
enzym
particip
tetrahydrofol
synthesi
ketoprofen
fastum
inhibit
prostaglandin
synthesi
largininenitr
oxid
pathway
diclofenac
sodium
voltarenxr
induc
antiinflammatori
antipyret
analges
action
inhibit
prostaglandin
synthesi
teriflunomid
aubagio
prolifer
activ
lymphocyt
depend
new
pyrimidin
synthesi
dihydroorot
dehydrogenas
inflammatori
activ
like
involv
b
cell
nanotechnologyan
overview
nanotechnolog
deal
manipul
issu
nuclear
level
creat
newer
novel
nano
materi
due
abil
produc
sophist
nanomateri
process
product
design
nanoscal
creat
addit
increment
recent
year
recent
mani
techniqu
develop
studi
physic
phenomena
construct
typic
nanomet
differ
nanomateri
term
smart
materi
util
describ
nanoparticl
focu
deliveri
drug
particular
organ
bodi
technolog
pave
way
past
sever
year
toward
expans
potenti
use
nanoparticl
cosmet
product
liposom
technolog
util
adjust
optic
properti
order
improv
solubl
alter
physic
properti
provid
hydrophil
vesicl
phosphatidylcholin
membran
nanomateri
use
medicin
field
therapeut
drug
deliveri
focu
treatment
variou
diseasesdisord
micro
nano
scale
system
maxim
efficaci
therapeut
treatment
numer
way
pave
abil
rapidli
detect
respond
diseas
state
directli
site
improv
patient
qualiti
life
nanoparticl
spheric
shape
particl
size
surfac
characterist
morpholog
nanoparticl
possess
essenti
role
toward
biodistribut
nanoparticl
ra
treatment
nanoparticl
np
util
therapeuticimag
agent
theranost
applic
encapsul
drug
contain
particl
help
afford
target
deliverycontrol
releas
encapsul
drug
physicochem
properti
associ
passiv
target
drug
ra
treatment
includ
particl
size
charg
shape
surfac
characterist
especi
nanoparticl
due
biocompat
biodegrad
properti
hold
vital
role
pharmaceut
industri
nanoparticl
conjug
specif
ligand
target
facilit
cellular
penetr
commonli
report
liposom
micel
metal
nanoparticl
polymer
nanoparticl
afford
effici
deliveri
toward
treatment
ra
nanoparticl
taken
system
circul
differ
process
adsorpt
ligand
receptor
attach
coval
coupl
intern
nsaid
base
deliveri
system
wide
report
ra
decreas
pain
analgesia
associ
earli
stage
ra
antiinflammatori
mechan
without
loss
articular
function
addit
block
enzym
play
essenti
role
gener
prostaglandin
drug
contain
nanoparticl
system
deliv
therapeut
inflam
synovium
metal
oxid
nanoparticl
reveal
variou
desir
characterist
drug
carrier
incred
higher
surfac
area
huge
pore
size
drug
encapsul
intrins
biodegrad
characterist
due
labil
metalligand
bond
versatil
function
post
synthet
graft
drug
molecul
rutin
stabil
silver
nanoparticl
elicit
antiinflammatori
activ
chronic
inflamm
critic
inhibit
creation
proinflammatori
cytokin
tumour
necrot
silver
nanoparticl
also
util
therapeut
benefit
ra
patient
lee
et
al
develop
hyaluron
gold
nanoparticletocilizumab
haaunptcz
complex
treatment
ra
util
immunosuppress
tocilizumab
monoclon
antibodi
target
receptor
synthesi
gold
nanoparticl
perform
use
citrat
method
attain
particl
diamet
nm
polydispers
index
haaunptcz
complex
found
tcz
steadili
releas
haaunp
tcz
complex
day
incub
bovin
serum
albumin
observ
antiangiogen
effect
develop
haaunptcz
complex
upon
prolifer
huvec
cell
bind
vegf
receptor
invivo
level
found
treatment
haaunptcz
complex
ra
induc
mice
exhibit
clear
interfac
cartilag
bone
compar
normal
group
without
ra
induc
confirm
western
blot
analysi
show
signific
upregul
express
level
indic
treatment
haaunptcz
complex
result
significantli
reduc
level
final
conclud
haaunptcz
complex
might
use
dual
target
drug
candid
vegf
receptor
treatment
ra
celecoxib
load
tristearin
base
lipid
nanoparticl
celtsln
synthes
kishor
et
al
check
effect
manag
ra
treatment
invitroinvivo
studi
util
celecoxib
select
inhibitor
oral
treatment
ra
util
statist
experiment
design
optim
nanoparticl
use
independ
variabl
homogen
speed
quantiti
tristearin
quantiti
emulsifi
depend
desir
particl
size
load
effici
drug
releas
observ
particl
size
nm
pdi
obtain
spheric
morpholog
xrd
result
indic
drug
dispers
molecular
level
lipid
matrix
also
rapid
quench
micro
emuls
prevent
drug
crystal
stage
invitro
drug
releas
studi
reveal
continu
drug
releas
within
h
found
drug
releas
follow
zero
order
fickian
diffus
pattern
invivo
studi
reveal
signific
reduct
inflamm
improv
lysosom
enzym
collagen
glycosamino
glycan
level
celtsln
treat
rat
compar
pure
drug
cel
treat
group
final
suggest
poorli
solubl
celecoxib
encapsul
tristearin
solid
lipid
nanoparticl
facilit
safe
efficaci
prolong
releas
characterist
enhanc
bioavail
chitosan
nanoparticl
chnp
load
dexamethason
dex
mtx
develop
kumar
et
al
effici
treatment
ra
prepar
chitosan
nanoparticl
use
ionic
gelat
method
entrap
effici
mtxchnp
dexchnp
found
respect
achiev
size
charg
chnp
mtxchnp
dexchnp
nm
pdi
nm
pdi
nm
pdi
mv
mv
mv
respect
ftir
result
confirm
phosphor
group
tripolyphosph
amin
group
chitosan
play
major
role
hydrogen
bond
formul
mtxchnp
dexchnp
observ
control
releas
pattern
coupl
diffus
drug
two
differ
buffer
ph
ph
respect
studi
cellular
behaviour
hek
murin
macrophag
cell
line
cell
line
ic
valu
mtxchnp
human
embryon
kidney
cell
raw
cell
line
ic
valu
mtxchnp
hek
cell
cell
cellular
uptak
studi
indic
intern
nanoparticl
phagocytosi
process
drug
releas
get
enhanc
lower
ph
increas
cytotox
insignific
exvivo
haemolysi
indic
higher
biocompat
nanoparticl
synthes
chnp
exhibit
maximum
absorpt
blood
circul
within
h
follow
hepat
metabol
renal
clearanc
final
observ
higher
antiarthrit
activ
antioxid
potenti
develop
nanoparticul
system
dewangan
et
al
synthes
curcumin
load
carboxi
methyl
cellulos
acet
butyr
nanoparticl
cmcab
flash
nano
precipit
method
use
multi
inlet
vortex
mixer
treatment
diseas
like
colon
cancer
pancreat
cancer
ra
alzheim
diseas
vari
reynold
number
inlet
stream
optim
nano
particl
size
averag
diamet
observ
size
around
nm
observ
synthes
nanoparticl
amorph
natur
found
nanoparticl
demonstr
especi
expand
absorpt
bioavail
drug
lead
effect
drug
administr
lee
et
al
examin
effect
arginineglycin
aspart
acid
rgd
attach
gold
half
shell
nanoparticl
contain
mtx
categori
dmard
treatment
ra
util
rgd
peptid
target
moieti
inflamm
nearinfrar
irradi
upon
develop
nanoparticl
gener
heat
due
gold
half
shell
mtx
get
rapidli
releas
synovi
inflamm
multipl
joint
may
target
penetr
depth
near
infrar
light
use
therapi
nanoparticl
smaller
dosag
mtx
solut
treatment
would
contribut
collageninduc
arthrit
mice
emphas
multifunct
nanoparticl
effect
maxim
therapeut
efficaci
minim
dosagerel
side
effect
treatment
ra
furthermor
show
nanoparticl
could
appli
dmard
treatment
ra
diseas
tacrolimu
tachsanp
load
albumin
nanoparticl
develop
thao
et
al
use
nanoparticl
albuminbound
technolog
improv
target
antiarthrit
efficaci
observ
averag
diamet
charg
nm
mv
respect
spheric
morpholog
encapsul
efficaci
tac
within
nanoparticl
water
solubl
develop
nanoparticl
get
increas
time
free
tac
tac
get
steadili
discharg
develop
np
h
provid
enough
time
target
treatment
inflam
arthrit
site
intraven
inject
invitro
studi
report
antiprolif
activ
tac
hsanp
monitor
upon
activ
cell
compar
nonactiv
cell
tac
hsanp
display
signific
higher
antiarthrit
potenti
tac
formul
compar
intraven
administ
tac
solut
oral
tac
suspens
reflect
incid
arthriti
clinic
score
vs
respect
henc
conclud
novel
tac
hsanp
may
effici
drug
deliveri
system
enhanc
solubl
increas
accumul
drug
joint
ra
treatment
differ
nanoparticul
base
deliveri
system
adopt
use
variou
drug
show
tabl
signific
nanoparticl
base
formul
treatment
ra
may
afford
improv
bioavail
increas
accumul
drug
diseas
inflam
site
prolong
releas
characterist
superior
level
nanoparticul
base
formul
may
also
elicit
target
potenti
specif
receptor
nanoemuls
isotrop
transpar
system
consist
oil
water
emulsifi
hold
averag
diamet
nm
emulsifi
play
essenti
role
settl
nanoemuls
repuls
electrostat
interact
steric
hindranc
expans
emulsifi
mandatori
product
smaller
size
droplet
decreas
interfaci
tension
surfac
energi
per
unit
rang
oil
water
phase
emuls
nanoemuls
report
enhanc
bioavail
efficaci
antiinflammatori
agent
nanoemuls
use
food
industri
flavor
nanoemuls
cosmet
industri
skin
hydrat
eas
applic
pharmaceut
field
nanoemuls
util
drug
deliveri
system
especi
parenter
oral
ocular
topic
administr
addit
nanoemuls
contain
build
block
complex
materi
compartment
nanoparticl
encapsul
oil
droplet
properti
associ
nanoemuls
high
surfac
area
per
unit
volum
robust
stabil
optic
transpar
tunabl
rheolog
mtx
load
lipid
nanoemuls
treatment
ra
develop
mello
et
al
determin
plasma
decay
curv
biodistribut
mtx
load
nanoemuls
radioact
count
method
antigen
induc
arthriti
rabbit
invivo
studi
reveal
mtx
load
nanoemuls
taken
mainli
liver
uptak
arthrit
joint
twofold
greater
control
joint
mtx
load
nanoemuls
treatment
reduc
leukocyt
influx
synovi
fluid
particular
mononuclear
polymorphonuclear
cell
reduc
respect
protein
leakag
arthriti
induc
rabbit
knee
also
limit
mtx
load
nanoemuls
treatment
commerci
mtx
treatment
result
indic
superior
antiinflammatori
effect
joint
rabbit
antigeninduc
arthriti
compar
commerci
mtx
hoscheid
et
al
develop
oil
base
novel
therapi
ra
treatment
sinc
pterodon
pubescen
oil
commonli
use
due
antirheumat
antinocicept
antiinflammatori
activ
optim
nanoemuls
compris
p
pubescen
oil
intramuscular
administr
estim
influenc
alter
ingredi
polysorb
peg
castor
oil
upon
physicochem
properti
formul
found
droplet
size
nanoparticl
around
nm
observ
pseudoplast
behavior
enabl
effect
may
found
suitabl
nano
emuls
base
ra
treatment
meloxicam
load
nanoemuls
transderm
deliveri
ra
develop
pathan
et
al
determin
solubl
meloxicam
differ
excipi
oil
surfact
cosurfact
found
viscos
nanoemuls
get
increas
increas
oil
content
observ
averag
particl
size
nm
polydispers
index
zeta
potenti
mv
percutan
permeat
meloxicam
load
nanoemuls
skin
observ
conclud
develop
meloxicam
load
nanoemuls
promis
vehicl
transderm
deliveri
ra
treatment
joint
diseas
mello
et
al
formul
lipid
nanoemuls
contain
mtx
increas
mtx
intraarticular
action
observ
antigeninduc
arthriti
aia
rabbit
subsequ
intraarticular
inject
antigen
h
treatment
dose
level
increas
ldemtx
compar
commerci
mtx
lde
alon
salin
control
uptak
radioact
lde
arthrit
joint
greater
normal
joint
treatment
intraarticular
ldemtx
elicit
clear
dose
respons
pattern
reduc
antirheumat
arthrit
effect
mtx
arginin
glycin
aspart
acid
peptid
conjug
gold
shell
nanoparticl
antiinflammatori
antirheumat
arthrit
effect
tacrolimu
human
serum
albumin
antirheumat
arthrit
effect
synovi
leukocyt
infiltr
p
protein
leakag
p
compar
arthrit
nontreat
joint
contrast
intraarticular
inject
commerci
mtx
lde
reduc
leukocyt
infiltr
protein
leakag
without
toxic
issu
treatment
period
associ
lipid
nanoemuls
mtx
present
mark
antiinflammatori
effect
absent
intraarticular
commerci
mtx
treatment
differ
nanoemuls
base
deliveri
system
adopt
use
variou
drug
show
tabl
signific
nanoemuls
base
formul
treatment
ra
may
afford
stabil
optic
transpar
inhibit
pglycoprotein
mediat
drug
efflux
promot
lymphat
transport
exhibit
tunabl
rheolog
effect
treatment
regimen
solid
lipid
nanoparticl
sln
colloid
carrier
particl
size
rang
nm
wide
util
control
drug
deliveri
merg
benefit
polymer
nanoparticl
oil
water
emuls
sln
possess
remark
properti
good
toler
protect
incorpor
activ
compound
chemic
degrad
higher
bioavail
incorpor
lipophil
hydrophil
drug
higher
drug
load
capac
rel
safe
biolog
applic
due
uniqu
size
rang
sln
rare
undergo
blood
clearanc
reticulo
endotheli
system
sln
made
physiolog
lipid
fatti
acid
phospholipid
monoditriglycerid
sln
may
prepar
variou
techniqu
high
shear
homogen
ultrasound
high
pressur
homogen
hot
homogen
cold
homogen
solvent
emulsif
evapor
method
recent
year
greater
attent
focus
toward
lipid
base
formul
improv
oral
bioavail
poorli
water
solubl
drug
use
sln
drug
carrier
combin
advantag
polymer
nanoparticl
fat
emuls
liposom
due
improv
physic
stabil
low
cost
eas
scaleup
produc
curcumin
load
solid
lipid
nanoparticl
csln
inflamm
overcom
poor
bioavail
issu
curcumin
develop
arora
et
al
observ
averag
particl
size
drug
content
entrap
effici
nm
mgml
examin
effect
pure
curcumin
csln
complet
freund
adjuv
cfa
induc
arthrit
rat
show
csln
act
carrier
effect
deliveri
curcumin
ra
patient
elicit
csln
show
antiarthrit
mechan
oxidoinflammatori
immunomodulatori
cascad
cfa
induc
arthriti
model
peng
et
al
develop
sln
sustain
releas
transderm
deliveri
piroxicam
pir
well
elucid
antiinflamm
effect
develop
sln
observ
pir
load
sln
possess
averag
particl
size
nm
pdi
charg
mv
howev
optim
formul
show
pirsln
spheric
shape
higher
entrap
effici
demonstr
sln
best
carrier
encapsul
sustain
releas
drug
pirsln
illustr
antiinflammatori
respons
edemat
site
reduc
secret
inflammatori
cytokin
piperin
load
solid
lipid
nanoparticl
psln
melt
emulsif
method
ra
treatment
formul
bhalekar
et
al
found
averag
diamet
nm
encapsul
charg
mv
invivo
pharmacodynam
studi
complet
freund
adjuv
induc
arthrit
rat
show
signific
reduct
treat
rat
might
mechan
behind
dmard
action
psln
raj
et
al
develop
aceclofenac
load
solid
lipid
nanoparticl
acfsln
incorpor
hydrogel
ultrason
emulsif
method
use
glyceryl
monostear
lipid
optim
basi
lipid
stir
speed
found
averag
particl
size
nm
polydispers
index
nm
zeta
potenti
mv
respect
optim
formul
observ
entrap
effici
invivo
studi
show
better
inhibit
edema
magnitud
h
compar
plain
acf
hydrogel
furthermor
optimum
size
sln
close
contact
stratum
corneum
improv
enhanc
skin
deposit
drug
therebi
emphas
acfsln
could
benefici
effect
ra
treatment
inject
actarit
load
solid
lipid
nanoparticl
asln
passiv
target
agent
ra
treatment
develop
ye
et
al
method
asln
use
target
spleen
elimin
advers
effect
nephrotox
upon
oral
administr
optim
formul
show
averag
size
nm
charg
mv
show
entrap
effici
load
asln
respect
achiev
plasma
concentr
asln
time
better
actarit
propylen
glycol
solut
howev
target
effici
asln
enhanc
spleen
renal
distribut
drug
get
significantli
reduc
compar
drug
solut
intraven
administr
mice
result
suggest
inject
asln
act
promis
passiv
target
therapeut
agent
reduc
dose
decreas
dose
frequenc
lower
toxic
ra
treatment
differ
sln
base
deliveri
system
adopt
use
variou
drug
show
tabl
signific
solid
lipid
nanoparticl
base
formul
treatment
ra
may
afford
controlledsustain
releas
pattern
lower
dose
frequenc
solid
lipid
base
nanoparticl
may
also
capac
enhanc
bioavail
encapsul
drug
ra
treatment
nanomicel
amphiphil
molecul
surfact
monom
polar
head
lipophil
tail
properti
relat
amphiphil
molecul
solut
result
development
structur
term
micel
micel
hold
intern
hydrophob
core
extern
hydrophil
surfac
micel
gener
made
monom
paramet
affect
micel
format
size
hydrophob
area
amphiphil
molecul
amphiphil
concentr
temperatur
solvent
polymer
micel
hold
diamet
nm
micellar
core
serv
compat
microenviron
center
point
join
water
insolubl
guest
molecul
hydrophob
molecul
coval
effect
coupl
block
copolym
physic
incorpor
hydrophob
micel
core
solubil
process
nanomicel
lead
enhanc
water
solubl
bioavail
cyclosporin
load
polysial
acidpolycaprolacton
micel
psapclcyanm
treatment
ra
develop
use
selfassembl
process
use
graft
technolog
wilson
et
al
howev
psapclcyanm
possess
load
capac
load
effici
precis
invitro
cellular
behaviour
studi
synovi
fibroblast
cell
line
indic
cya
get
releas
psapcl
micel
subsequ
uptak
synovi
fibroblast
nonreceptor
mediat
endocytosi
partit
cya
phospholipid
membran
crielaard
et
al
develop
dexamethasoneload
polymer
micel
dexpm
treatment
ra
observ
averag
diamet
nm
pdi
howev
highli
effici
encapsul
dex
deriv
attain
drugpolym
ratio
ww
confirm
effect
develop
formul
invivo
adjuv
induc
arthriti
model
final
suggest
treatment
dexpm
show
immedi
prolong
antiarthrit
effect
anim
model
emphas
dexpm
significantli
effect
free
dex
term
inhibit
arthriti
score
p
day
p
day
onward
minim
degre
ankl
swell
zhang
et
al
develop
indomethacin
load
polymer
micel
indnm
conjug
amphiphil
polyphosphazen
poli
nisopropylacrylamid
ethyl
adjac
group
thermal
ring
open
polymer
invivo
pharmacodynam
studi
perform
acut
paw
edema
adjuv
arthriti
model
indic
sustain
therapeut
efficaci
could
achiev
local
intraarticular
inject
indnm
furthermor
suggest
amphiphil
copolym
could
util
inject
drug
carrier
hydrophob
drug
wang
et
al
develop
lowdos
glucocorticoid
therapi
util
micel
load
dexamethason
dex
synthes
polymer
micel
use
poli
ethylen
glycol
blockpoli
pclpeg
selfassembl
process
dex
incorpor
pclpeg
micel
show
encapsul
critic
micellar
concentr
cellular
behaviour
raw
cell
show
viabil
wherea
free
drug
show
viabil
result
confirm
conjug
pclnpc
pclpeg
nmr
analysi
found
dexnm
may
afford
target
deliveri
inflam
joint
indic
potenti
dexnm
lower
dose
treatment
inflammatori
diseas
helmi
et
al
develop
larnoxicam
load
nanomicel
lxnm
direct
equilibrium
techniqu
ra
treatment
hydrodynam
diamet
poli
dispers
index
lxnm
found
nm
respect
invivo
studi
reveal
lxnm
exhibit
better
inhibitori
effect
carrageenaninduc
edema
free
lx
lxnm
show
effect
compar
diclofenac
studi
period
day
signific
reduct
edema
percentag
increas
weight
growth
emphas
lxnm
consid
ra
treatment
inflammatori
disord
differ
nanomicellar
base
deliveri
system
adopt
use
variou
drug
show
tabl
signific
nanomicel
base
formul
treatment
ra
may
afford
tendenc
break
beyond
critic
micellar
concentr
longer
circul
behaviour
sustain
releas
effect
improv
bioavail
enhanc
solubl
increas
accumul
drug
diseas
inflam
site
prolong
effect
nanocapsul
submicron
size
formul
rang
nm
contain
one
activ
materi
core
form
protect
matrix
shell
therapeut
substanc
may
form
liquidsolidmolecular
dispers
surround
polymer
membran
nanocapsul
recent
attract
signific
interest
due
protect
coat
gener
pyrophor
get
effect
oxid
main
advantag
nanocapsul
toward
drug
deliveri
applic
sustain
releas
properti
increment
drug
select
improv
bioavail
allevi
drug
toxic
addit
polymer
nanocapsul
enhanc
safeti
efficaci
drug
increas
aqueou
solubl
protect
degrad
control
releas
enhanc
bioavail
tissu
select
diversifi
applic
nanocapsul
variou
field
includ
agrochem
genet
engin
cosmet
wastewat
treatment
adhes
compon
applic
deliveri
drug
tumour
radiotherapi
liposom
nanocapsul
food
scienc
agricultur
bernardi
et
al
synthes
indomethacinload
nanocapsul
indnc
evalu
acut
sub
chronic
edema
experiment
rat
model
compar
result
free
indomethacin
employ
invivo
model
carrageenaninduc
acut
oedema
subchron
oedema
cfainduc
arthriti
develop
indnc
potent
subchron
cfa
induc
arthriti
model
compar
pure
indomethacin
howev
cfa
arthriti
model
treat
indnc
markedli
inhibit
serum
level
proinflammatori
cytokin
tumour
necrosi
factor
sequenti
level
antiinflammatori
cytokin
significantli
increas
indic
gastrointestin
damag
indnc
treat
anim
significantli
lesser
comparison
indomethacin
treat
group
result
suggest
formul
might
repres
promis
altern
treat
chronic
inflammatori
diseas
decreas
undesir
effect
friedrich
et
al
develop
tacrolimu
load
lipid
core
nanocapsul
taclcnc
afford
system
antiarthrit
properti
use
selfassembl
process
show
unimod
particl
size
distribut
averag
particl
size
nm
pdi
encapsul
invivo
studi
elicit
anim
treat
taclcnc
show
signific
inhibit
paw
oedema
intraperiton
administr
suggest
lcnc
potenti
prevent
hyperglycemia
mediat
advers
effect
drug
conclud
taclcnc
serv
novel
nanomedicin
treatment
inflammatori
diseas
boechat
et
al
develop
mtxload
lipid
core
nanocapsul
mtxlcnc
observ
averag
particl
size
encapsul
effici
nm
respect
observ
mtxlcnc
reduc
serum
level
mtxlcnc
show
efficaci
decreas
proinflammatori
cytokin
tcellderiv
cytokin
interferongamma
mtx
solut
furthermor
conclud
formul
effect
toward
inflamm
control
dose
lower
convent
mtx
invivo
antioedematogen
activ
polyphenol
resveratrol
quercetin
coencapsul
lipidcor
nanocapsul
complet
freund
adjuv
induc
arthriti
model
studi
coradini
et
al
observ
inhibit
among
day
day
arthriti
induct
major
histolog
chang
fibrosi
synovi
tissu
cartilag
bone
loss
unlik
convent
arthriti
treatment
drug
coencapsul
lipidcor
nanocapsul
alter
hepat
biochem
marker
alp
alkalin
phosphat
alt
alanin
aminotransferas
ast
aspart
aminotransferas
final
conclud
lipidcor
nanocapsul
may
efficaci
oedematogen
agent
without
hepatotox
effect
rollett
et
al
develop
folic
acid
fa
function
human
serum
albumin
nanocapsul
hsanc
target
deliveri
chronic
activ
macrophag
specif
ra
treatment
use
method
avoid
toxic
crosslink
chemic
emulsifi
optim
formul
show
averag
size
nm
polydispers
index
confirm
fa
distribut
surfac
hsa
nanocapsul
threedimension
fluoresc
label
confoc
laser
scan
microscopi
clsm
besid
particular
bind
intern
hsanc
macrophag
acquir
human
peripher
blood
mononuclear
cell
demonstr
flow
cytometri
macrophag
demonstr
expand
bind
fa
modifi
capsul
compar
without
fa
folat
base
nanocarri
may
use
target
activ
macrophag
without
affect
normal
cell
ra
treatment
differ
nanocapsul
base
deliveri
system
adopt
use
variou
drug
show
tabl
signific
nanocapsul
base
formul
treatment
ra
may
afford
longer
site
specif
dose
retent
rapid
absorpt
drug
improv
bioavail
higher
dose
load
control
releas
effect
enhanc
solubl
improv
therapeut
effect
recent
sirna
peptid
target
approach
base
nanoformul
approach
attempt
effect
treatment
ra
fig
differ
approach
focuss
toward
treatment
ra
shown
sirna
base
nanoparticul
system
treatment
ra
cellular
mechan
respons
posttranscript
gene
silenc
act
messeng
rna
mrna
term
rna
interfer
rnai
silenc
attain
small
interfer
rna
sirna
transient
henc
novel
strategi
develop
report
achiev
perman
silenc
vector
encod
strategi
short
hairpin
rna
shrna
may
also
use
longterm
stabl
cell
silenc
approach
due
excel
gene
silenc
potenti
rnai
attract
broad
attent
term
high
specif
signific
effect
minor
side
effect
eas
synthesi
sirna
capac
silenc
specif
gene
interest
problem
associ
nake
sirna
upon
system
administr
degrad
nucleas
ultim
shorten
sirna
circul
time
blood
stream
moreov
sirna
get
engulf
receptor
mediat
endocytosi
therebi
escap
endosom
compart
decreas
therapeut
efficaci
nake
sirna
howev
issu
recent
address
develop
nanotechnolog
base
product
order
afford
better
protect
sirna
encapsul
posit
charg
particl
effect
protect
serum
degrad
offtarget
immunolog
effect
recent
sirna
base
deliveri
system
util
treatment
ra
especi
provid
effici
distribut
peripher
inflam
tissu
rna
interfer
major
phenomena
mediat
small
interf
rna
sirna
effect
gene
silenc
high
degre
specif
komano
et
al
develop
wrapsom
ws
contain
sirna
core
compos
cation
lipid
bilay
sirna
complex
envelop
neutral
lipid
bilay
polyethylen
glycol
surfac
sirnaw
check
therapeut
activ
collagen
induc
arthriti
cia
mice
model
intraven
dose
sirnaw
show
efficaci
sirnatarget
tumor
necrosi
factor
cia
mice
arthriti
score
quantifi
mrna
level
joint
realtim
revers
transcriptasepolymeras
chain
reaction
observ
intens
fluoresc
remain
higher
h
inject
sirnaw
combin
macrophag
neutrophil
inflam
synovium
suggest
express
variou
molecul
associ
pathogenesi
ra
henc
conclud
treatment
sirnaw
reduc
mrna
level
joint
compar
control
group
final
emphas
effici
deliveri
sirna
arthrit
joint
scheinman
et
al
develop
rgd
function
sirnaload
poli
lactidecoglycolid
plga
nanoparticl
np
nanosystem
deliveri
sirna
joint
tissu
cia
mous
model
observ
nanoparticl
properti
stabil
sirna
encapsul
morpholog
examin
reveal
size
rang
rgdnp
nm
net
posit
charg
may
due
rgd
function
plga
np
protect
sirna
serum
degrad
presenc
rgd
peptid
np
outer
surfac
increas
tissu
uptak
fold
arthrit
mice
rgd
function
increas
lung
deliveri
nanoparticl
arthrit
mice
compar
control
group
rgd
function
plga
nanoparticl
encapsul
sirna
may
effect
treatment
arthriti
possibl
select
inhibit
macrophag
dendrit
cell
activ
lee
et
al
develop
nanocomplex
polymer
sirna
polysirna
focus
thiolat
glycol
chitosan
tgc
polym
treatment
ra
show
polysirna
form
selfpolymer
thiol
group
end
sens
antisens
strand
sirna
encapsul
tgc
polym
result
polysirnatgc
nanoparticl
psitgcnp
averag
diamet
nm
macrophag
cultur
system
psitgcnp
show
rapid
cellular
uptak
excel
invitro
gene
silenc
efficaci
addit
psitgcnp
show
higher
accumul
arthrit
joint
site
cia
mice
matrix
metalloproteinas
nanoprob
micro
comput
tomographi
result
show
intraven
inject
psitgcnp
significantli
inhibit
inflamm
bone
eros
cia
mice
compar
mtx
mgkg
therefor
avail
psitgcnp
therapi
target
specif
cytokin
may
herald
new
era
treatment
ra
park
et
al
develop
plga
nanoparticl
load
dexamethason
sirna
treatment
ra
dexamethason
initi
load
plga
nanoparticl
drugload
plga
nanoparticl
complex
poli
ethyleneimin
pei
sirna
assess
codeliveri
sirna
dexamethason
human
chondrocyt
cell
line
cell
transfect
green
fluoresc
protein
sirna
gfp
sirna
drug
transfect
gfp
sirna
reduct
cell
demonstr
gfp
express
wherea
mock
carri
plga
nanoparticl
plga
nanoparticl
without
sirna
show
remark
differ
gfp
express
combin
dexamethason
sirna
treatment
clearli
reduc
express
inflammatori
apoptosi
relat
factor
produc
cell
induc
enter
inflammatori
state
tnfa
ngml
induc
nitric
oxid
ino
product
cell
examin
pretreat
induc
express
arthritisrel
molecul
invitro
final
conclud
reduct
gene
protein
express
associ
arthriti
transfect
dexamethasoneload
sirnacomplex
plga
nanoparticl
desai
et
al
design
cyclic
cation
head
lipidpolym
hybrid
nanocarri
cylipn
encapsul
antinocicept
agent
capsaicin
cap
sirna
treatment
chronic
skin
inflamm
physicochem
character
includ
hydrodynam
size
surfac
potenti
entrap
efficaci
cylipn
found
nm
mv
respect
cap
invitro
skin
distribut
studi
show
cylipn
could
effect
deliv
fitcsirna
skin
depth
enhanc
cap
permeat
cylipn
observ
compar
capsaicinsolut
capzasinhp
therapeut
efficaci
cylipn
assess
use
imiquamodinduc
psoriat
plaqu
model
cylipn
carri
cap
show
signific
reduc
express
gene
compar
either
drug
alon
close
comparison
duan
et
al
design
core
shell
nanoparticl
load
sirna
effect
treatment
arthriti
prepar
nano
carrier
polyethyleneimin
pei
super
paramagnet
iron
oxid
nanoparticl
spio
compos
core
iron
oxid
shell
pei
deliveri
sirna
nanoparticl
administ
intraven
arthrit
rat
analyz
cellular
uptak
tissu
distribut
therapeut
effect
sirna
receptor
b
chain
peispiodeliv
sirna
accumul
easili
inflam
joint
effici
taken
joint
macrophag
cell
invitro
studi
suggest
peispio
load
sirna
exhibit
neglig
cytotox
improv
sirna
stabil
induc
specif
gene
silenc
invitro
peifunction
spio
use
system
sirna
deliveri
ra
enhanc
therapeut
benefit
applic
extern
magnet
field
drug
deliveri
system
improv
therapeut
efficaci
specif
toward
treatment
variou
disord
use
activ
target
ligand
antibodi
peptid
polysaccharid
two
mode
target
activ
passiv
treatment
ra
nanoparticul
formul
target
toward
select
express
surfac
receptor
mediat
growth
factor
proinflammatori
cytokin
chemokin
cell
adhes
molecul
proteas
play
vital
role
ra
develop
strategi
angiogenesi
inflamm
condit
associ
ra
progress
folat
receptorbeta
vasoact
intestin
peptid
vip
receptor
scaveng
receptor
class
tolllik
receptor
transform
growth
factorbeta
receptor
express
macrophag
wherea
integrin
eselectin
vascular
cell
adhes
intercellular
cell
adhes
predominantli
express
angiogen
condit
mtxload
poli
lacticcoglycol
acid
plga
gold
au
iron
fe
gold
au
halfshel
nanoparticl
np
combin
arginineglycineaspart
acid
rgd
develop
kim
et
al
accomplish
averag
diamet
np
nm
estim
mtx
load
wt
nearinfrar
nir
irradi
heat
gener
inflam
site
due
nir
reson
au
halfshel
mtx
releas
plga
nanoparticl
found
fe
halfshel
layer
insert
au
halfshel
layer
facilit
invivo
reson
mr
imag
besid
nir
absorb
imag
moreov
distribut
nanoparticl
inflam
region
collageninduc
arthrit
cia
mice
retent
enhanc
influenc
extern
magnet
field
combin
success
nir
irradi
extern
magnet
field
result
higher
therapeut
effect
compar
convent
treatment
despit
use
mtx
dosag
dosag
np
jain
et
al
develop
algin
base
nanoparticl
encapsul
antiinflammatori
cytokin
encod
plasmid
dna
found
averag
particl
size
unmodifi
np
nm
modifi
surfac
nanocarri
scrambl
tuftsin
peptid
particl
size
found
nm
nm
respect
spheric
morpholog
nanoparticl
treatment
arthrit
rat
significantli
reduc
system
joint
tissu
proinflammatori
cytokin
express
prevent
progress
inflamm
joint
damag
reveal
magnet
reson
imag
histolog
observ
enhanc
local
tuftsinpeptid
modifi
algin
nanoparticl
limb
arthrit
anim
compar
unmodifi
scrambledpeptid
modifi
nanoparticl
consequ
singl
dose
target
formul
load
plasmid
dna
demonstr
superior
transfect
effici
sustain
local
system
express
lead
allevi
proinflammatori
cytokin
reduct
paw
edema
target
algin
nanoparticl
load
plasmid
dna
effici
repolar
macrophag
state
offer
novel
treatment
chronic
inflammatori
diseas
gener
normal
inflammatori
process
resolut
mediat
sever
agonist
among
glucocorticoid
regul
protein
call
annexin
also
play
vital
role
proreslov
action
annexin
mediat
nformyl
peptid
receptor
fredman
et
al
mimick
receptor
activ
aminotermin
peptid
encompass
amino
acid
ac
coload
collagen
iv
col
iv
target
nanoparticl
np
accomplish
particl
size
around
nm
charg
mv
col
ivac
np
col
ivac
np
administ
preexist
lesion
lead
improv
protect
collagen
layer
overli
lesion
decreas
lesion
collagenas
activ
decreas
plaqu
necrosi
suppress
oxid
stress
thu
administr
resolutionmedi
peptid
col
ivac
np
activ
receptor
myeloid
cell
stabil
advanc
atherosclerot
lesion
invivo
studi
suggest
mice
lack
myeloid
cell
nt
show
improvementsthes
find
support
concept
defect
inflamm
resolut
play
role
advanc
atherosclerosi
suggest
new
form
therapi
yang
et
al
select
target
synovi
joint
autoimmun
arthriti
joint
vasculatur
util
adjuv
induc
arthriti
model
human
rheumatoid
arthriti
profil
synovi
vasculatur
exvivo
invivo
defin
phage
peptidedisplay
librari
found
synthet
peptid
show
bind
jointderiv
endotheli
cell
well
specif
inhibit
bind
respect
phage
synovi
vasculatur
intriguingli
treatment
arthrit
rat
one
peptid
result
effici
inhibit
arthriti
progress
howev
suppress
arthriti
achiev
via
peptideinduc
reduct
tcell
traffick
joint
inhibit
angiogenesi
furthermor
peptid
differ
sequenc
receptor
bind
specif
angiogenesisinflammationrel
cell
signal
previous
character
arginineglycineaspart
acidcontain
peptid
show
peptid
exploit
select
distribut
antiarthrit
agent
inflam
joint
improv
efficaci
reduc
system
toxic
peptid
recent
gain
keen
interest
toward
drug
deliveri
variou
therapeut
approach
bioactiv
peptid
deriv
natur
protein
sourc
milk
egg
plant
fish
meat
etc
upon
enzymat
proteolysi
exert
biolog
activ
variou
disord
peptid
exhibit
antihypertens
antiinflammatori
antidiabet
anticanc
antimicrobi
antioxid
properti
casein
hydrolys
effect
inflamm
problem
associ
peptid
low
bioavail
metabol
liabil
degrad
gastro
intestin
tract
low
absorpt
inabl
cross
epitheli
barrier
solidphas
peptid
synthesi
ringopen
polymer
protein
engin
techniqu
util
incorporateassembl
peptid
nanostructur
nanoparticul
selfassembl
differ
form
peptid
dipeptid
cyclic
peptid
amphiphil
peptid
peptid
peptid
util
recent
peptid
base
deliveri
system
util
treatment
ra
especi
natur
sourc
synthet
peptid
zhou
et
al
found
melittinderiv
cation
amphipath
peptid
combin
sirna
act
activ
target
agent
subunit
nfk
b
administr
sirna
nanocomplex
modul
inflammatori
cytokin
product
express
specif
joint
protect
bone
eros
preserv
cartilag
integr
identifi
sirna
nanocomplex
potent
suppress
earli
inflammatori
arthriti
without
affect
express
offtarget
organ
elicit
humor
immun
respons
serial
inject
result
suggest
selfassembl
sirna
nanocomplex
act
nontox
platform
specif
deliveri
sirna
target
constrain
inflammatori
process
treatment
varieti
diseas
protein
citrullin
import
posttransl
modif
increas
attent
particularli
involv
ra
tutturen
et
al
evalu
citrullinom
ra
synovi
fluid
direct
lcmsm
analysi
perform
enrich
approach
base
citrullin
specif
biotinyl
techniqu
analys
ra
synovi
fluid
deplet
abund
protein
total
deplet
fraction
suggest
total
deplet
synovi
fluid
enrich
found
respect
wherea
without
enrich
show
citrullin
peptid
frequenc
citrullin
peptid
degre
citrullin
determin
four
known
ra
autoantigen
well
novel
invivo
auto
citrullin
site
peptidylarginin
deiminas
result
indic
direct
analysi
allow
identif
one
fraction
citrullin
protein
present
synovi
fluid
specif
enrich
still
need
comprehens
indepth
elucid
citrullinom
shen
et
al
design
immunomodulatori
peptid
target
tcell
receptor
tcr
critic
play
major
role
immun
diseas
autoimmun
arthriti
use
signal
chain
homo
oligomer
school
approach
acut
respiratori
syndrom
coronaviru
sarscov
fusion
peptid
sequenc
target
tcr
addit
tcr
core
peptid
shown
treatment
human
cellmedi
dermatos
substitut
corticosteroid
incorpor
peptid
selfassembl
lipopeptid
nanoparticl
mimic
nativ
human
high
densiti
lipoprotein
essenti
increas
peptid
dosag
efficaci
found
peptid
improv
collageninduc
arthriti
j
mice
ensur
bone
cartilag
damag
rush
et
al
develop
degrad
nondegrad
poli
nipamamp
nanoparticl
encapsul
cellpenetr
antiinflammatori
peptid
kafak
suppress
proinflammatori
cytokin
inflam
cartilag
explant
check
kafakload
poli
nipamamp
activ
invitro
human
macrophag
model
human
monocyt
exvivo
bovin
knee
cartilag
tissu
poli
nipamamp
result
show
dosedepend
suppress
proinflammatori
cytokin
upon
treatment
kafakload
poli
nipamamp
nanoparticl
demonstr
select
target
therapeut
efficaci
kafak
releas
degrad
nondegrad
poli
nipamamp
nanoparticl
invitro
exvivo
model
emphas
poli
nipamamp
nanoparticl
load
kafak
could
effect
tool
treatment
osteoarthr
natur
therapi
physic
therapi
occup
therapi
psychosoci
therapi
relevantli
support
cure
autoimmun
inflammatori
diseas
ra
present
eventhough
combinatori
therapi
provid
better
respons
aspect
select
toxic
healthi
cell
creat
major
issu
futur
treatment
option
ra
treatment
apart
nanoparticul
formul
may
focu
toward
develop
select
inhibitor
proinflammatori
cytokin
virtu
applic
monoclon
antibodi
bioactiv
peptid
sirna
base
deliveri
system
molecular
biolog
comput
chemistri
orient
focuss
may
offer
better
design
develop
formul
specif
target
proinflammatori
cytokin
interest
toward
develop
nanoformul
treatment
ra
increas
recent
year
due
versatil
applic
nanoformul
possess
versatil
properti
biocompat
reduc
dose
frequenc
lower
dose
improv
efficaci
sustain
effect
decreas
advers
effect
nanosystem
provid
system
topic
oral
deliveri
antirheumat
arthrit
drug
glucocorticoid
nsaid
etc
review
may
permit
basic
idea
focu
nano
base
therapeut
approach
use
pharmaceut
drug
sirna
peptid
phytoconstitu
effect
treatment
ra
